Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | RecQ helicase-like | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Giardia lamblia | U5 small nuclear ribonucleoprotein 200 kDa helicase, putative | RecQ helicase-like | 649 aa | 521 aa | 19.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | DNA helicase recq, putative | 0.0024 | 0.3847 | 0.5 |
Trypanosoma brucei | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 0.3847 | 0.5 |
Plasmodium vivax | ADP-dependent DNA helicase RecQ, putative | 0.0012 | 0.0146 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 1 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 1 | 1 |
Loa Loa (eye worm) | ATP-dependent DNA helicase | 0.0024 | 0.3847 | 1 |
Treponema pallidum | ATP-dependent DNA helicase | 0.0012 | 0.0146 | 0.5 |
Loa Loa (eye worm) | RecQ helicase | 0.0024 | 0.3847 | 1 |
Entamoeba histolytica | recQ family DNA helicase | 0.0012 | 0.0146 | 0.0146 |
Schistosoma mansoni | DNA helicase recq1 | 0.0024 | 0.3847 | 0.3847 |
Schistosoma mansoni | blooms syndrome DNA helicase | 0.0012 | 0.0146 | 0.0146 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0024 | 0.3847 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0146 | 0.00000000841 |
Plasmodium falciparum | ADP-dependent DNA helicase RecQ | 0.0024 | 0.3847 | 0.5 |
Plasmodium falciparum | ATP-dependent DNA helicase Q1 | 0.0024 | 0.3847 | 0.5 |
Trichomonas vaginalis | DNA helicase recq1, putative | 0.0024 | 0.3847 | 0.5 |
Trypanosoma cruzi | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 0.3847 | 1 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0012 | 0.0146 | 0.0381 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.3847 | 1 |
Giardia lamblia | Sgs1 DNA helicase, putative | 0.0024 | 0.3847 | 0.5 |
Trichomonas vaginalis | DNA helicase recq, putative | 0.0024 | 0.3847 | 0.5 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0024 | 0.3847 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Leishmania major | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 0.3847 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Entamoeba histolytica | recQ family helicase, putative | 0.0024 | 0.3847 | 0.3847 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Schistosoma mansoni | DNA helicase recq5 | 0.0024 | 0.3847 | 0.3847 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 4.4668 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1). (Class of assay: confirmatory) [Related pubchem assays: 594 (Rhodamine region spectral profiling screen), 593 (Fluorescein region spectral profiling screen), 2367 (Probe Development Summary for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)), 2353 (qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1))] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.